Bio Stocks™

Big Pharma M&A set for mega year as patent expiries drive deal urgency. $XBI $IBB If the current pace holds, 2026 biopharma M&A could top $250 billion, making it the #2 year on record after 2019’s $328 billion. #biotech ca.finance.yahoo.com/news/big-pharm…

$TRVI PT raised to $31 at B. Riley

@monaco_biotech EMA is awaiting an update on the inspection classification of Catalent Indiana from the FDA 😬

$SRRK Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA) • BioPharmCatalyst biopharmcatalyst.com/company/SRRK/n…

$NUVB announces updated positive follow-up data from the Phase 2 study of safusidenib in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma. ORR rate of 52% and 36 month PFS rate of 79% with nearly 40 months of follow-up prnewswire.com/news-releases/…

$BMY to Build the Most Powerful AI Factory in Life Sciences with $NVDA BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models and compress discovery timelines. $ABSI $RXRX news.bms.com/news/corporate…

$GLSI Provides Clinical Updates on FLAMINGO-01 Phase 3 Trial investor.greenwichlifesciences.com/news-events/pr…

$SEER BoD Unanimously Rejects Unsolicited Acquisition Proposal from CEO to Acquire Seer for $2.45/share

Biotech IPO momentum continues to accelerate - 7 companies filed in the past week alone. $XBI 📈🚀 $NUOX $BLSM $ATTO $BRVE $TARX $VOGX $LTGO

$MANE is the best performing biotech IPO of the year by a mile. $XBI 📈 Up ~550% from $17 IPO price and still ripping! 💥

@JonahLupton True! 😂

@BioStocks Or you could just buy the stocks

Kalshi to Offer Sports-Style Betting on Drug Trial Results and FDA Regulatory Decisions. 🎲 theguardian.com/technology/202…

🧬 Biotech Weekly News Largest single-day stock moves during the week ending 07/17/26 🟢 $NXTC 202% Merger with Avere Therapeutics $QTTB 91% Positive Results Bempikibart trial $AGEN 83% Oversubscribed Private Placement $ATAI 33% $LLY to Acquire AtaiBeckley $XNCR 17% Oral Presentation for XmAb819 Study 🔴 $SNTI -40% Transaction for Gene-Circuit Pipeline $SPRO -22% Exclusive License for IBI355 $CELC -18% FDA Approval of REVTORPYK™ $CVKD -16% Phase 2 Data for CAD-1005 $ABOS -12% EBD Program Data See image & the reply below for details.

$RGNX $100M offering priced at $9/share

$GSK acquired Camlipixant from the BELLUS acquisition back in 2023 for $2B gsk.com/en-gb/media/pr…

Whoa! $GSK to discontinue further development of Camlipixant in RCC. gsk.com/en-gb/media/pr…

$GUTS MS view one- year data as encouraging ahead of key topline REMAIN-1 pivotal cohort data expected in early 4Q26. PT$2

$ABUS Receives $178M First Payment From Moderna Settlement Agreement - Expects to return up to ~$230M in capital to Arbutus shareholders

$ALDX Requests Clarification From the FDA on Reproxalap NDA Meeting Minutes sec.gov/ix?doc=/Archiv…

$ATAI $2.50/share CVR breakdown - - $1/share upon initiation of a Phase 3 trial of VLS-01 prior to the 4th anniversary of closing - $0.50/share upon U.S.regulatory approval and DEA rescheduling of BPL-003 prior to the 5th anniversary of closing - $1/share upon U.S. regulatory approval and DEA rescheduling of VLS-01 prior to the 7th anniversary of closing

$LLY nears deal to buy psychedelic drugmaker $ATAI bloomberg.com/news/articles/…

$CRDF $10M Direct Offering at $1.05/share